Therapy for Kaposi's sarcoma: Recent advances and experimental approaches

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 4 SUPPL., 1999, Pages

  Yarchoan, Robert ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Angiogenesis; Human herpesvirus type 8; Kaposi's sarcoma; Liposomal anthracyclines; Paclitaxel; Therapy

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BLEOMYCIN; CHORIONIC GONADOTROPIN; CILENGITIDE; DOXORUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTERLEUKIN 12; PACLITAXEL; SEMAXANIB; THALIDOMIDE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CRYOTHERAPY; DRUG EFFECT; HUMAN; KAPOSI SARCOMA; PRIORITY JOURNAL; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CYCLOHEXANES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOSOMES; NEOPLASMS; PACLITAXEL; SARCOMA, KAPOSI; SESQUITERPENES; THALIDOMIDE; TRETINOIN;

HERPESVIRIDAE;

EID: 0033178423     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (82)

1. Mitsuyasu RT, Taylor JMG, Glaspy J, Fahey JL. Heterogeneity of epidemic Kaposi's sarcoma. Implications for therapy. Cancer 1986;57:1657-61.
2. Yarchoan R, Venzon DJ, Pluda JM, et al. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med 1991;15:184-9.
3. Jones JL, Hanson DL, Ward JW. Effect of antiretroviral therapy on recent trends in cancers among HIV-infected persons [abstract]. J Acquir Immune Defic Syndr Hum. Retrovirol 1998;17:A38 (Abstract S3).
4. Rabkin C, Testa M, A., Fischl M, Von Roenn J. Declining incidence of Kaposi's sarcoma in AIDS Clinical Trial Group (ACTG) trials [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:A39.
5. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995;332:1181-5.
6. Chang Y, Cesarman E, Pessin M, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
7. Krown SE, Real FX, Cunningham-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983;308: 1071-6.
8. Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:671-6.
9. Gelmann EP, Preble OT, Steis R, et al. Human immunoblastoid interferon treatment of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Am J Med 1985;78:737-41.
10. Volberding PA, Abrams DI, Conant M, Kaslow K, Vranizan K, Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:335-8.
11. Laubenstein L, Krigel RL, Odajnyk C, et al. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 1984;2:1115-20.
12. Gill PS, Rarick M, McCutchan JA, et al. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991;90:427-33.
13. Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993;341: 1242-3.
14. Bogner J, Kronawitter U, Rolinski B, Truebenbach K, Goebel F. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 1994;7:463-8.
15. Harrison M, Tomlinson S, S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995; 13:914-20.
16. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995;13:996-1003.
17. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997;15:653-9.
18. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14: 2353-64.
19. Northfelt DW, Dezube B, Thommes J, et al. Randomized comparative trial of Doxil vs. adriamycin, bleomycin, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi's sarcoma (AIDS-KS). 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., U.S.A., 1996.
20. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 1998;16:683-91.
21. Mitsuyasu R, von Roenn J, Krown S, et al. Comparison study of liposomal doxorubicin (Dox) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi's sarcoma (AIDS-KS): AIDS Clinical Trial Group (ACTG) protocol 286, American Society for Clinical Oncology, Denver, Colorado, U.S.A., 1997.
22. Arbuck SG, Dorr A, Friedman MA. Paclitaxel (Taxol) in breast cancer. Hematol Oncol Clin North Am 1994;8:121-40.
23. Rowinsky E, Donehower P. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-13.
24. Saville MW, Lietzau J, Pluda JM, et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995;346: 26-8.
25. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998;16:1112-21.
26. Gill PS, Scadden DT, Groopman J, et al. Low dose paclitaxel (Taxol) is highly effective in the treatment of patients with advanced AIDS-related Kaposi's sarcoma [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:A35.
27. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997;90: 3789-98.
28. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4- T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
29. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-7.
30. D'Amato R, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91: 4082-5.
31. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
32. Nakamura S, Salahuddin SZ, Biberfeld P, et al. Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4 T cells. Science 1988;242:426-30.
33. Ensoli B, Nakamura S, Salahuddin SZ, et al. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989;243:223-6.
34. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994;371:674-80.
35. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997;24: 203-18.
36. Wellstein A, Zugmaier G, Califano JAD, Kern F, Paik S, Lippman ME. Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 1991;83:716-20.
37. Pluda JM, Shay LE, Foli A, et al. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993;85:1585-92.
38. Figg WD, Pluda JM, Lush RM, et al. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 1996; 17:91-7.
39. Pluda JM, Wyvill K, Lietzau J, et al. A phase I trial of TNP-470 (AGM-1470) administered to patients with HIV-associated Kaposi's sarcoma (KS), The First National Conference on Human Retroviruses and Related Infections, Washington, D.C., U.S.A., 1993.
40. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-82.
41. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
42. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
43. Welles L, Little R, Wyvill K, et al. Preliminary results of a phase II study of oral thalidomide in patients with HIV infection and Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:A21.
44. Bower M, Howard M, Gracie F, Phillips R, Fife K, Centre K. A phase II study of thalidomide for Kaposi's sarcoma: Activity and correlation with KSHV DNA load [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:A35.
45. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998;16:1444-9.
46. Clerici M, Lucey DR, Berzofsky JA, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262:1721-4.
47. Chougnet C, Wynn TA, Clerici M, et al. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis 1996;174:46-53.
48. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-62.
49. Sgadari C, Angiolillo AL, Cherney BW, et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 1996;93:13791-6.
50. Geras-Raaka E, Varma A, Ho H, Clark-Lewis I, Gershengorn MC. Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J Exp Med 1998;188:405-8.
51. Foli A, Saville MW, Baseler MW, Yarchoan R. Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication. Blood 1995;85:2114-23.
52. Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997;19:237-44.
53. Fischl MA, Finkelstein DM, He W, Powderly WG, Triozzi PL, Steigbigel RT. A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:379-84.
54. Miles SA, Rezai AR, Salazar-Gonzalez JF, et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990;87:4068-72.
55. Corbeil J, Rapaport E, Richman DD, Looney DJ. Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells. J Clin Invest 1994;93:1981-6.
56. Sidell N, Taga T, Hirano T, Kishimoto T, Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol 1991;146:3809-14.
57. Gill PS, Espina BM, Moudgil T, et al. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: Results of a pilot phase II study. Leukemia 1994;8:S26-32.
58. Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with Interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995;13:1966-74.
59. Von Roenn J, von Gunten C, Mullane M, French S, Blough R, Benson AB, III. All-transretinoic acid (TRA) in the treatment of AIDS-related Kaposi's sarcoma [abstract PO-B12-1571], Abstracts of the IX International Conference on AIDS, IV STD World Congress, vol. 1. 1993:397.
60. Adamson PC, Boylan JF, Balis FM, et al. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res 1993;53:472-6.
61. Aboulafia D, Norris D, Grossman RJ, et al. Interim analysis of phase II study (protocol L-1057-28) of Panretin capsules (LGD1057, ALRT1057) for AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:A24.
62. Friedman-Kien A, Dezube B, Lee J, et al. Oral 9-cis retinoic acid is active in AIDS related Kaposi's sarcoma: AIDS Associated Malignancy Consortium Study 002 [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:A24.
63. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990;335:123-8.
64. Gao S-J, Kingsley L, Zheng ML, et al. KSHV antibodies among Americans, Italians, and Ugandans with and without Kaposi's sarcoma. Nature Med 1996;2:925-8.
65. Lennette E, Blackbourn DJ, Levy JA. Antibodies to human herpes virus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996;348:858-61.
66. Lundardi-Iskandar Y, Bryant JL, Zeman RA, et al. Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 1995;375:64-8.
67. Lunardi-Iskandar Y, Bryant JL, Blattner WA, et al. Effects of a urinary factor from women in early pregnancy on HIV-1, SIV and associated disease. Nat Med 1998;4:428-34.
68. Gill PS, Lunardi-Ishkandar Y, Louie S, et al. The effects of preparations of human chorionic gonadotropin on AIDS- related Kaposi's sarcoma. N Engl J Med 1996;335:1261-9.
69. Gill PS, McLaughlin T, Espina BM, et al. Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma. J Natl Cancer Inst 1997;89:1797-1802.
70. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996;274:1739-44.
71. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines [see comments]. Science 1997;278:290-4.
72. Staskus KA, Zhong W, Gebhard K, et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997;71:715-9.
73. Humphrey RW, O'Brien TR, Newcomb FM, et al. Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells (PBMCs): association with KS and persistence in patients receiving anti-herpes drugs. Blood 1996;88: 297-301.
74. Morfeldt L, Torssander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994;26:749-52.
75. Humphrey RW, Davis DA, Newcomb FM, Yarchoan R. Human herpesvirus 8 (HHV-8) in the pathogenesis of Kaposi's sarcoma and other diseases. Leuk Lymphoma 1998;28:255-64.
76. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997;99:2082-6.
77. Davis DA, Humphrey RW, Newcomb FM, et al. Detection of serum antibodies to a Kaposi's sarcoma-associated herpesvirus-specific peptide. J Infect Dis 1997;175:1071-9.
78. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990;345:84-6.
79. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immunodeficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989;7:1201-7.
80. Little RF, Pluda JM, Feigal E, Yarchoan R. The challenge of designing clinical trials for AIDS-related Kaposi's sarcoma. Oncology 1998;12:871-83.
81. Wit FW, Sol CJ, Renwick N, et al. Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. AIDS 1998;12:218-9.
82. Feigal EG, Von Roenn J, Justice R, et al. Kaposi's sarcoma response criteria: issues identified by the National Cancer Institute, Food and Drug Administration, and the AIDS Malignancy Consortium [abstract 24]. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:A22.